Hope Neuron is developing SELanetx™, a non-drug immune-reset therapy targeting ALS and neurodegenerative disease. Join the campaign.
ALS kills motor neurons. The body's immune system — meant to protect — turns against it. Conventional medicine manages symptoms but doesn't stop the progression.
Ronald Lane is a biologist with an engineer's mind and a husband's heart. When Alzheimer's began taking his wife Sandy, he didn't reach for existing treatments. He asked a different question: what if we could reset the immune system itself?
That question became a decade of research.
Today, the science is ready. HOPE-Neuron is in the late stages of developing the first non-drug, immune-reset platform for neurodegenerative disease, starting with ALS. The SELanetx™ system is a device-enabled, outpatient therapy that reprograms immune dysfunction at its root cause.
With strong preclinical results, globally protected IP, and academic partners in place, HOPE-Neuron is moving toward first-in-human trials. This raise puts investors in at the inflection point.
"What if we could reset the immune system itself?"
In our ALS preclinical study, SELanetx™ produced a measurable M1-to-M2 immune cell shift — the same mechanism we're targeting in humans. The result: improved motor function in ALS-model mice. p<0.008. That's not a promise. That's data.
SELanetx™ works by drawing a small amount of your blood, applying oxygen and pressure to activate a natural cellular process, and returning it — now carrying signals that tell your immune system to stop attacking and start healing. It's a 30-minute, closed-loop procedure that works without foreign substances or long-term pharmaceutical dependency.
A small sample — less than a typical blood donation — is drawn in a standard clinical setting.
A closed-loop device applies precise oxygen and pressure to activate cells that naturally signal your immune system to stand down.
The treated blood is returned. Your immune system receives a signal to stop attacking and start healing — no foreign substances required.
The next study is at Barrow Neurological Institute. It's staffed and ready, pending this campaign. Every dollar moves us closer to a human trial for ALS. This is your chance to own a piece of that moment.
"I'm betting my own money on this. I hope you will too."
MS. Alzheimer's. Parkinson's. Selected cancers. The same immune rebalancing mechanism that targets ALS is applicable across the spectrum of neurodegenerative disease.
Advancing toward first-in-human trials at Barrow Neurological Institute.
The same immune rebalancing mechanism that targets ALS applies directly to Alzheimer's pathology.
MS involves immune dysfunction at the root — SELanetx™ is designed for exactly this class of disease.
Neuroinflammation drives Parkinson's progression; the platform targets that pathway.
Immune modulation opens doors to oncology applications under active investigation.
ALS doesn't wait.
Neither should this.
